• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconWegovy

Wegovy

Page 5 of 6
woman measures her waist
HealthWeaning off Ozempic slowly instead of quitting abruptly can help prevent patients from regaining weight, study says
By Ashleigh Furlong and BloombergMay 11, 2024
Lars Fruergaard Jorgensen, chief executive officer Novo Nordisk
RetailDenmark’s Novo Nordisk forecasts 27% sales surge but faces price pressure amid Eli Lilly competition
By Naomi Kresge and BloombergMay 2, 2024
Novo Nordisk CEO Lars Fruergaard Jorgensen Interview
RetailNovo Nordisk’s market value of $570 billion is now bigger than the entire Danish economy—creating a ‘Nokia risk’ for Denmark
By Sanne Wass, Naomi Kresge and BloombergMay 1, 2024
Lars Fruergaard Jorgensen
HealthNo evidence Ozempic and Wegovy raise risk of self harm, EU regulators said
By Jonel Aleccia and The Associated PressApril 12, 2024
HealthStudy shows Wegovy eases heart-failure symptoms for patients with diabetes—helpful to Novo as it argues insurers should pay for it
By Naomi Kresge and BloombergApril 6, 2024
HealthOzempic maker Novo Nordisk facing pressure as study finds $1,000 appetite suppressant can be made for just $5
By Madison Muller, Robert Langreth and BloombergMarch 28, 2024
A person using Ozempic
RetailWegovy and Ozempic have ignited a gold rush in pharma as well as an upsurge in fake ‘skinny jabs’, leading to surge in hospitalizations
By Ashleigh Furlong and BloombergMarch 13, 2024
tube of wegovy injections
LifestyleNovo Nordisk eclipses Tesla on positive trial results for a weight loss drug that may be more powerful than its own Wegovy 
By Prarthana PrakashMarch 8, 2024
Health62-year-old who lost 40 pounds in 9 months on Wegovy wants to stop the treadmill: ‘At some point you have to come off of them. I don’t want to be on them forever’
By Jonel Aleccia and The Associated PressMarch 7, 2024
Still life of Wegovy an injectable prescription weight loss medicine that has helped people with obesity.
RetailNovo Nordisk’s Wegovy and Ozempic boom saved Denmark’s GDP from a no-growth 2023—and will help double its expected growth this year, country’s largest bank says
By Niclas Rolander and BloombergMarch 5, 2024
RetailNovo Nordisk’s CEO says he’s fielding calls from ‘scared’ junk food suppliers asking for advice over Ozempic surge
By Ryan HoggFebruary 8, 2024
Lars Fruergaard Jorgensen holding flashcards and talking
RetailNovo Nordisk CEO says he was ‘surprised’ to see the popularity of weight-loss drugs in Europe—and people’s readiness to pay out of pocket for them
By Prarthana PrakashFebruary 5, 2024
RetailNovo Nordisk hits $500B market value, climbing closer to the $1T club as it forecasts Wegovy and Ozempic will juice another 29% jump in profits this year
By Ryan HoggJanuary 31, 2024
HealthNorth Carolina drops coverage for Wegovy and Ozempic, with implications for anti-obesity drug market projected to hit $100B by 2030
By Simone Foxman, Madison Muller and BloombergJanuary 27, 2024
HealthOzempic, Wegovy demand so strong Europe’s most valuable listed company plans ‘mega manufacturing facility’
By Ellie Harmsworth and BloombergDecember 24, 2023
1
  • 2
  • 3
  • 4
  • 5
  • 6
6
Most Popular
Success
Covid gave us hybrid work. The Iran War might give us a four-day week—and this time, experts say it could stickAn image of a popular article
By Fortune EditorsMarch 21, 2026
AI
'Godfather of AI' says tech companies aren’t concerned with the AI endgame. They’re focused on short-term profits insteadAn image of a popular article
By Fortune EditorsMarch 21, 2026
AI
A man let ChatGPT sell his home. It beat every agent's estimate by $100K—and closed in 5 daysAn image of a popular article
By Fortune EditorsMarch 21, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.